trial · primary record
Erdafitinib Intravesical Delivery System
Non-Muscle Invasive Bladder Neoplasms
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 235 |
| Primary completion | 2029-07-24 |
| Primary endpoint | Parts 1 to 3: Number of Participants with Adverse Events (AEs) |
| Registry ID | NCT05316155 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:56.636Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05316155
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Erdafitinib Intravesical Delivery System · compound